Gliomas are classified in astrocytic, oligodendroglial, and ependymal tumors showing WHO grades I-IV. Glioblastoma (grade IV glioma) shows a high invasive and proliferative capacity. The overall median survival of patients suffering from glioblastoma is 14.6 months after surgical resection and radiotherapy/chemotherapy because recurrence following treatments is very elevated. In addition to these procedures, several therapies against glioma have been tested such as intranasal drug delivery, gene therapy, immunotherapy, and microRNA. Despite these new therapeutic procedures, the median survival time of glioma patients is very low and hence new therapeutic strategies must be urgently developed to treat the disease.
To improve the diagnosis and treatment of pediatric and adult gliomas, new specific antitumor strategies showing increased anti-glioma effects and decreased toxicity must be explored and developed. Glioma cells show resistance to antitumor therapies, leading to glioma cell proliferation, survival, invasion, and metastasis which are regulated by different ligands, receptors, and intracellular cascades controlling the genetic and protein machinery of glioma cells; new anti-glioma drugs must specifically block these cellular events. This has opened novel research lines to explore new and promising therapeutic strategies focused on targetable molecules.
This Research Topic aims to identify potential and promising molecular targets against glioma, develop novel compounds capable of specifically destroying glioma cells, and counteracting glioma development. New anticancer strategies targeting glioma-specific molecular derangements must serve to improve the diagnosis and treatment of glioma and increase the quality of life and cure rate of patients with glioma.
We particularly welcome studies on:
• Potential targetable molecules involved in the proliferation, survival, invasion, and metastasis of glioma cells such as epigenetic regulatory proteins, DNA damage repair enzymes, signal transduction molecules, kinases, peptides, and transcription factors.
• New antiproliferative, antimetastatic, and antiangiogenic strategies against glioma, as well as signal transduction inhibitors, gene expression modulators, hormone therapies, cytotoxic peptide-conjugate-based cancer therapy, apoptotic inducers, and peptide-receptor radionuclide therapy.
• Function-structure relationships between ligands and receptors for the design and synthesis of new and higher effective anti-glioma compounds
• Glioma microenvironment, glioma stem cells, blood-brain barrier, glioma microvessels, glioma biomarkers, and drug repurposing against glioma.
Original research, systematic reviews, reviews, mini reviews, perspectives, clinical trials, case reports, brief research reports, and opinions focused on any aspect of glioma are welcome.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in Frontiers in Oncology.
Gliomas are classified in astrocytic, oligodendroglial, and ependymal tumors showing WHO grades I-IV. Glioblastoma (grade IV glioma) shows a high invasive and proliferative capacity. The overall median survival of patients suffering from glioblastoma is 14.6 months after surgical resection and radiotherapy/chemotherapy because recurrence following treatments is very elevated. In addition to these procedures, several therapies against glioma have been tested such as intranasal drug delivery, gene therapy, immunotherapy, and microRNA. Despite these new therapeutic procedures, the median survival time of glioma patients is very low and hence new therapeutic strategies must be urgently developed to treat the disease.
To improve the diagnosis and treatment of pediatric and adult gliomas, new specific antitumor strategies showing increased anti-glioma effects and decreased toxicity must be explored and developed. Glioma cells show resistance to antitumor therapies, leading to glioma cell proliferation, survival, invasion, and metastasis which are regulated by different ligands, receptors, and intracellular cascades controlling the genetic and protein machinery of glioma cells; new anti-glioma drugs must specifically block these cellular events. This has opened novel research lines to explore new and promising therapeutic strategies focused on targetable molecules.
This Research Topic aims to identify potential and promising molecular targets against glioma, develop novel compounds capable of specifically destroying glioma cells, and counteracting glioma development. New anticancer strategies targeting glioma-specific molecular derangements must serve to improve the diagnosis and treatment of glioma and increase the quality of life and cure rate of patients with glioma.
We particularly welcome studies on:
• Potential targetable molecules involved in the proliferation, survival, invasion, and metastasis of glioma cells such as epigenetic regulatory proteins, DNA damage repair enzymes, signal transduction molecules, kinases, peptides, and transcription factors.
• New antiproliferative, antimetastatic, and antiangiogenic strategies against glioma, as well as signal transduction inhibitors, gene expression modulators, hormone therapies, cytotoxic peptide-conjugate-based cancer therapy, apoptotic inducers, and peptide-receptor radionuclide therapy.
• Function-structure relationships between ligands and receptors for the design and synthesis of new and higher effective anti-glioma compounds
• Glioma microenvironment, glioma stem cells, blood-brain barrier, glioma microvessels, glioma biomarkers, and drug repurposing against glioma.
Original research, systematic reviews, reviews, mini reviews, perspectives, clinical trials, case reports, brief research reports, and opinions focused on any aspect of glioma are welcome.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in Frontiers in Oncology.